SUNNYVALE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the first quarter of 2025 after the close of trading on Thursday, May 8, 2025. Company management will host a conference call to discuss... Read More

SUNNYVALE, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for... Read More

SUNNYVALE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 & Recent Highlights Reported total revenue of $18.5 million in the fourth quarter of... Read More

SUNNYVALE, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, and Scott Blumberg, CFO, will participate in a fireside chat at the upcoming 45 th Annual TD Cowen Health Care Conference. The fireside chat... Read More

SUNNYVALE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the fourth quarter and full year of 2024 after the close of trading on Tuesday, February 25, 2025. Company management will host a conference... Read More

SUNNYVALE, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Ceribell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming 43 rd Annual J.P. Morgan Healthcare Conference. The presentation will take place on Monday, January 13, 2025,... Read More

Ms. Rodenbush to lead hiring and talent development initiatives Mr. Price to focus on market development and penetration SUNNYVALE, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- CeriBell, Inc . (Nasdaq: CBLL), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions (“Ceribell”), today announced the appointments of Kristie Rodenbush as Chief People Officer... Read More

SUNNYVALE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended September 30, 2024. Third Quarter 2024 & Recent Highlights Reported total revenue of $17.2 million in the third quarter of 2024, a 48% increase... Read More

Ceribell System stands to reduce costly ICU admissions and intra-facility patient transfers Military veterans face elevated risks of developing seizure disorders SUNNYVALE, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions (“Ceribell”), today announced the receipt of an... Read More

SUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Scott Blumberg, CFO, will participate in a fireside chat at the upcoming Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum. The fireside chat will take... Read More

SUNNYVALE, Calif. , Oct. 29, 2024 /PRNewswire/ -- Ceribell, Inc. (Nasdaq: CBLL) ("Ceribell"), a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the third quarter of 2024 after the close of trading on Tuesday, November 12, 2024 . Company management will host a conference... Read More

Five abstracts presented at the 2024 Neurocritical Care Society Annual Meeting demonstrated the clinical impact of the FDA-cleared Ceribell System and Ceribell's AI-powered Clarity™ algorithm Clarity remains first and only device FDA 510(k) cleared for the diagnosis of electrographic status epilepticus SUNNYVALE, Calif. , Oct.... Read More

SUNNYVALE, Calif. , Oct. 15, 2024 /PRNewswire/ -- CeriBell, Inc. (Nasdaq: CBLL) ("Ceribell"), a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, announced today the closing of its upsized initial public offering of 12,196,969 shares of its common stock at a public offering price of $17.00 per share, which includes 1,590,909... Read More

SUNNYVALE, Calif. , Oct. 10, 2024 /PRNewswire/ -- CeriBell, Inc. (Nasdaq: CBLL) ("Ceribell"), a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, announced today the pricing of its upsized initial public offering of 10,606,060 shares of its common stock at a public offering price of $17.00 per share. In connection with the... Read More